BridgeBio Pharma
BBIO
201 hedge funds and large institutions have $8.7B invested in BridgeBio Pharma in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 81 increasing their positions, 60 reducing their positions, and 27 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 60
11% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 27
1% more funds holding
Funds holding: 199 → 201 (+2)
0.88% more ownership
Funds ownership: 94.71% → 95.6% (+0.88%)
0% more capital invested
Capital invested by funds: $8.69B → $8.7B (+$9.98M)
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
60% less call options, than puts
Call options by funds: $19.2M | Put options by funds: $48.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$26M |
| 3 |
PCIG
Partners Capital Investment Group
Boston,
Massachusetts
|
+$25M |
| 4 |
BlackRock
New York
|
+$24.4M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$100M |
| 2 |
SUT
SC US (TTGP)
Menlo Park,
California
|
-$39.1M |
| 3 |
Two Sigma Investments
New York
|
-$26.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$23.3M |
| 5 |
BAMCO Inc
New York
|
-$18.4M |
BBIO Hedge Fund Activity: Q2 2021 in Review
201 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2021, worth a combined $8.7B — up 0.11% from $8.69B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new BBIO positions and 27 closed out — a net gain of 3 holders — while 81 added to existing stakes and 60 trimmed.
The largest buyer was Vanguard Group, adding an estimated $114M. The largest seller was Darwin Global Management, cutting an estimated $100M.
- 201 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2021, up from 199 in Q1 2021.
- Funds reported $8.7B of BridgeBio Pharma stock for Q2 2021, up 0.11% quarter-over-quarter.
- 30 funds opened new BridgeBio Pharma positions in Q2 2021 and 27 closed out, a net change of +3 holders.
- The largest BridgeBio Pharma buyer in Q2 2021 was Vanguard Group, an estimated $114M added.
- The largest BridgeBio Pharma seller in Q2 2021 was Darwin Global Management, an estimated $100M sold.
Based on aggregated 13F filings for Q2 2021.